Dupilumab showed superiority to tralokinumab among patients with AD, although the absolute differences were small among responders.
From pre- to postmenopause, there is a decline in crude overall American Heart Association's Life's Essential 8 (LE8) score.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results